top of page

Free Biopharma Daily Stock Updates - 08/10/21

  • Writer: BPIQ
    BPIQ
  • Aug 10, 2021
  • 2 min read

$XBI $126.48 -0.81%

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Pipeline Updates

$ADMA -0.7% ADMA Biologics Advances Expansion Plans and Opens New Plasma Collection Center in Conyers, GA; ADMA Implements Haemonetics’ Persona Technology for NexSys Plasma Collection System. source


$ATHX +4.6% Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke. source


$PHAS -2.4% PhaseBio Pharmaceuticals and SFJ Pharmaceuticals® Announce Approval of IND Application in China for Bentracimab. source


$IFRX -3.0% InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum. source


$KLDO -2.4% Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical Trial. source


$IMV +8.9% IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer. source


$TRVN +2.1% Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy. source


$FULC +125.3% Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease. source


$FNCH +1.5% Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program. source


$JAZZ -4.2% GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex. source


$IMPL -25.9% Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021. source


$RETA -18.1% Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs. source


$ZIOP -16.2% Ziopharm Oncology Provides Second Quarter 2021 Corporate Updates. source


$NEXI +18.1% NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates. source


$CRTX +21.5% Cortexyme Provides Business Update and Reports Second Quarter 2021 Results. source


$ACHL +22.1% Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights. source


$ORPH +24.6% On 8/5 New publication date for Orphazyme’s Interim Report H1 2021. source



Financial Updates

$FULC +125.3% Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock. source


$PTGX +1.1% Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma. source


$LMNL -17.8% Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M. source


$BCRX -13.9% BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants. source

Posted by FS

 
 
 

Comments

bottom of page